AUA

The hematuria monitor (HM) was discussed in a late-breaking abstract at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

At 2, 3, and 5 weeks after surgery, the stone removal rate was higher in the test group vs the control group (P < .05).

Neoadjuvant axitinib facilitated partial nephrectomy in patients with an imperative indication for nephron-sparing surgery but no viable strategy to receive the procedure.

“Our results showed significant improvement in postoperative urgency and UUI (P = .005) with no significant change in IIEF-5 score at 6-month follow-up compared to baseline,” wrote the authors.

The IELT significantly increased by 3.22-fold in the Mini-patch device group, compared with the sham group (P = .0047).

“This study demonstrates the superiority of the SP in patient-reported cosmetic and pain outcomes on short- and long-term follow-up after uro-oncological surgical procedures,” the study authors concluded.

“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.

“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”

“SWIU has just, in my humble opinion, gained incredible traction in the last few years, and it's a really great organization,” says Kara L. Watts, MD.

The OS was significantly longer in the avelumab plus BSC vs BSC alone arm in all randomized patients, as well as in patients with PD-L1-positive tumors.

Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.

“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.

At a median follow-up of 20.7 months in patients with papillary disease (n = 77), the median DFS was 23.6 months.

Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.

"A single dose of URO-902 24 mg or 48 mg was associated with clinically relevant improvement in efficacy and quality of life and was safe and well tolerated," says Kenneth M. Peters, MD.

“From our standpoint, bigger prostates bleed more…From that, we started taking a different approach for those larger prostates,” says Andrew Higgins, MD.

"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.

“The idea that Aquablation [treats] any size and any shape of prostate really does seem to hold true for these cohorts of patients,” says Dean Elterman, MD, MSc, FRCSC.

“The main advantages with regard to the Zenflow Spring System are that there's no piercing, there's no trauma, and there's no heat involved with the treatment,” says Peter Chin, MD.

To examine the disparities of ED diagnosis and referral, Denise Asafu-Adjei, MD, MPH, and a team of investigators conducted a study involving 2 outpatient urology settings who serve communities with varying demographics.

"Although the effects of a plant-based diet on the cardiovascular system and endocrine system are well-documented and very well-studied, the effect on erectile function [is not fully understood]," says Ruben Blachman-Braun, MD.

Senior author Peter N. Schlegel, MD, FACS, recently presented updates to the AUA/ASRM guideline for the diagnosis and treatment of infertility in men at the 2021 AUA Annual Meeting.

“[Rezum] does give men another option, and so I think that's…really what we're focusing on here: giving the option to avoid general anesthesia and to avoid a bigger surgery,” says Michael A. Palese, MD.

“We're getting close, and we hope to have things concluding here soon and then to be able to offer some of these technologies on a on a wider scale,” says Mathew D. Sorensen, MD, MS, FACS.

“I’m looking forward to comparisons of minimally invasive surgery versus medical therapy, that is, at this point, untapped. It's something which we think we have insight into, but we really don't have good data,” says Kevin T. McVary, MD.

In a study presented at the 2021 AUA Annual Meeting, Karim Chamie, MD, and coauthors further examine the long-term results of UGN-101 for patients with LG UTUC given the favorable outcomes of the initial OLYMPUS trial.

Mathew D. Sorensen, MD, MS, FACS, and a team of investigators recently assessed the efficacy and safety of ultrasonic propulsion treatment on patients with kidney stones.

“We were able to show that there was a very…clinically significant decrease in the rate of UTIs in the vaccinated group, preventing UTIs in almost 60% of vaccinated patients,” says J. Curtis Nickel, MD.

In a recent study presented at the 2021 AUA Annual Meeting, Naeem Bhojani, MD, FRCSC, David-Dan Nguyen, and co-authors reported the favorable 3-year results of ongoing Aquablation research specifically involving patients with large prostates.

“Figuring out a good, comfortable way to bring that [ED] conversation up…will really pay dividends in other parts of the health care system. It will also allow more people to appropriately get funneled to urology to better address it,” says Denise Asafu-Adjei, MD, MPH.